Latest news with #IL12
Business Wire
25-04-2025
- Business
- Business Wire
Obsidian Therapeutics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design update on the ongoing multicenter study Agni-01 (NCT06060613), Obsidian will share preclinical data from our cytoDRiVE ® platform demonstrating spatiotemporal regulation of membrane-bound IL12 in syngeneic solid tumor models and preclinical data on OBX-115 TIL phenotype starting from NSCLC tumor tissue. Obsidian is presenting new preclinical data from its cytoDRiVE regulation platform, further demonstrating the ability to unlock the therapeutic window of potent cytokines and broaden the reach of armored cell therapies. The poster for abstract LB025 demonstrates the application of Obsidian's regulatable cytoDRiVE platform to enhance antigen-responsive ('spatial') promoter-induced activation by adding a critical pharmacologically regulatable ('temporal') signal to exert tight 'spatiotemporal' control over IL12 expression 1, resulting in a positive impact on safety and tumor control in syngeneic solid tumor models. Obsidian will also present preclinical data from a multimodal phenotyping analysis comparing OBX-115 TIL generated with its proprietary manufacturing process to conventional, non-engineered TIL using NSCLC tumor samples. The poster for abstract LB359 provides evidence that, as observed with melanoma 2, the OBX-115 process generates a minimally exhausted, CD8+ enriched and memory 'stem-like' T-cell phenotype. Additionally, the tumor reactive gene signature analysis showed that the drug product is enriched for putative tumor-reactive T-cell clonotypes. Obsidian Posters at AACR 2025: Spatiotemporally regulated expression of membrane-bound interleukin 12 (mbIL12) for armored adoptive cell therapy (ACT) shows strong antitumor activity in syngeneic solid tumor models without overt toxicity (Abstract LB025) Presenting Author: Ross T, Obsidian Therapeutics Poster: Sunday, April 27, 2:00-5:00pm CT OBX -115 TIL from non-small cell lung cancer (NSCLC) are enriched for putative tumor-reactive, stem-like T cells with enhanced tumor cytotoxicity: Results from multimodal phenotyping analysis (Abstract LB359) Presenting Authors: Schoenfeld AJ, Memorial Sloan Kettering Cancer Center Poster: Tuesday, April 29, 2:00-5:00pm CT Trial in progress: Phase 1/2 study of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced solid tumors (Abstract CT244) Presenting Author: Shoushtari AN, Memorial Sloan Kettering Cancer Center 1 Smith et al., SITC 2024 (Abstract 463). 2 Bernatchez et al., ISCT 2024 (Abstract 909). About OBX-115 Obsidian's lead investigational cytoTIL15™ program, OBX-115, is a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte [TIL] cell therapy) armored with pharmacologically regulatable membrane-bound IL15 (mbIL15). OBX-115 has the potential to become a meaningful therapeutic option for patients with advanced or metastatic melanoma and other solid tumors by leveraging the expected benefits of mbIL15 and Obsidian's proprietary, differentiated manufacturing process to enhance persistence, antitumor activity, and clinical safety of TIL cell therapy. Obsidian is investigating OBX-115 in the phase 1/2 Agni-01 multicenter trial in patients with advanced solid tumors (NCT06060613). About Obsidian Therapeutics Obsidian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian's proprietary cytoDRiVE ® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs. Obsidian is headquartered in Cambridge, MA. For more information, please visit and follow us on LinkedIn.
Associated Press
25-03-2025
- Business
- Associated Press
KaliVir Immunotherapeutics Announces Details of Presentation at 2025 American Association for Cancer Research (AACR) Annual Meeting
KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a poster at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025 in Chicago, IL. The presentation will focus on the company's clinical oncolytic immunotherapy, VET3-TGI, for patients with incurable, advanced solid tumors. VET3-TGI is a novel oncolytic immunotherapy which is designed to systemically target and selectively kill tumor cells while also expressing an immuno-stimulatory transgene payload consisting of interleukin-12 and a TGFbeta inhibitor. Details on the poster presentation are below: Presentation Title: Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI Abstract Number: 484 Session Date & Time: Sunday, April 27, 2025; 2-5 pm Presenter: Stephen Thorne, PhD, Co-founder and Chief Scientific Officer, KaliVir Immunotherapeutics About KaliVir Immunotherapeutics, Inc. KaliVir Immunotherapeutics is a clinical-stage biotechnology company at the forefront of developing next-generation oncolytic immunotherapies. By harnessing the unique advantages of the vaccinia platform, KaliVir engineers optimized viral backbones to create innovative candidates for cancer treatment. The Company's proprietary Vaccinia Enhanced Template (VET ™ ) platform integrates multiple genetic modifications, allowing for the systemic delivery of oncolytic vaccinia candidates and the targeted expression of therapeutic transgenes within tumors. The Company is actively expanding its pipeline using the VET ™ platform, with its capabilities validated through strategic global partnerships with Astellas Pharma and Roche. Currently, the Company has two product candidates in Phase 1 clinical trials: ASP1012, exclusively licensed and led by Astellas Pharma, and its internal lead candidate, VET3-TGI. With multiple therapeutic candidates progressing through clinical development, KaliVir is positioned as a leader in innovative cancer therapies. Headquartered in Pittsburgh, Pennsylvania, KaliVir is committed to revolutionizing cancer treatment. For more information, visit Lauren Arnold SOURCE: KaliVir Immunotherapeutics, Inc. Copyright Business Wire 2025. PUB: 03/25/2025 04:45 PM/DISC: 03/25/2025 04:45 PM
